China Universal Asset Management Co. Ltd. Has $17.51 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

China Universal Asset Management Co. Ltd. increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 71.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 54,338 shares of the medical research company’s stock after buying an additional 22,603 shares during the period. Amgen accounts for approximately 1.9% of China Universal Asset Management Co. Ltd.’s holdings, making the stock its 10th biggest position. China Universal Asset Management Co. Ltd.’s holdings in Amgen were worth $17,508,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of AMGN. Strategic Financial Concepts LLC bought a new stake in shares of Amgen during the 2nd quarter worth $26,000. Hershey Financial Advisers LLC bought a new stake in shares of Amgen during the 2nd quarter worth $30,000. nVerses Capital LLC acquired a new position in Amgen during the 2nd quarter valued at $31,000. Bbjs Financial Advisors LLC acquired a new position in Amgen during the 2nd quarter valued at $33,000. Finally, Matrix Trust Co acquired a new position in Amgen during the 3rd quarter valued at $36,000. 76.50% of the stock is owned by institutional investors.

Amgen Trading Up 0.1 %

Shares of Amgen stock opened at $317.17 on Tuesday. The stock has a market capitalization of $170.14 billion, a P/E ratio of 45.31, a price-to-earnings-growth ratio of 2.86 and a beta of 0.61. The company has a quick ratio of 0.89, a current ratio of 1.26 and a debt-to-equity ratio of 9.64. The company has a 50-day simple moving average of $325.27 and a 200 day simple moving average of $314.44. Amgen Inc. has a 12-month low of $249.70 and a 12-month high of $346.85.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). The firm had revenue of $8.39 billion for the quarter, compared to analyst estimates of $8.35 billion. Amgen had a return on equity of 161.72% and a net margin of 10.12%. The company’s revenue for the quarter was up 20.1% compared to the same quarter last year. During the same quarter last year, the business earned $5.00 EPS. Research analysts expect that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be issued a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 2.84%. The ex-dividend date of this dividend is Monday, November 18th. Amgen’s dividend payout ratio is currently 128.57%.

Analysts Set New Price Targets

Several research firms recently commented on AMGN. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $305.00 target price (down from $310.00) on shares of Amgen in a research note on Wednesday, August 7th. Dbs Bank upgraded shares of Amgen to a “strong-buy” rating in a research note on Monday, September 16th. Robert W. Baird reiterated an “underperform” rating and set a $215.00 target price on shares of Amgen in a research note on Wednesday, September 25th. Truist Financial cut shares of Amgen from a “buy” rating to a “hold” rating and upped their target price for the company from $320.00 to $333.00 in a research note on Monday, October 14th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $380.00 target price (up from $375.00) on shares of Amgen in a research note on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $332.55.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.